Overview

• The ESSENCE Phase III trial demonstrated semaglutide's efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH), resolving liver inflammation in 63% of patients and improving fibrosis in 37%.
• Participants receiving semaglutide experienced significant weight loss, averaging 10.5% of body weight, compared to 2% in the placebo group.
• MASH, a severe form of fatty liver disease linked to obesity and diabetes, affects 5–7% of U.S. adults and can lead to cirrhosis, liver failure, or cancer.
• Adverse effects of semaglutide were primarily gastrointestinal, with low discontinuation rates, highlighting its tolerability in long-term use.
• Novo Nordisk has submitted semaglutide for FDA approval to treat MASH, with a priority review decision expected by the end of 2025.